Dr Khalil on Benefits Derived From the POSEIDON Regimen in Metastatic NSCLC

Maya Khalil, MD, discusses the use of first-line durvalumab plus tremelimumab in patients with non–small cell lung cancer enrolled in the phase 3 POSEIDON trial, and sheds light on histologies and mutations that are associated with increased benefit with this regimen.

Related Keywords

Maya Khalil ,Division Of Hematology ,Oneal Comprehensive Cancer Center ,University Of Alabama At Birmingham ,O Neal Comprehensive Cancer Center ,Nivolumab And Ipilimumab ,Checkmate 227 ,Checkmate 9la ,Chemotherapy ,Non Small Cell Lung Cancer ,